Dentsply Sirona (XRAY) shares plunged 5.07% on Friday following the company's Q4 2024 earnings report, which showed a wider net loss of $910 million and earnings per share of -$4.48 that missed analyst expectations. The dental equipment maker's revenue also declined 4.3% year-over-year.
In the wake of the weak results, several analysts downgraded their ratings and price targets on XRAY. Bank of America lowered its target to $19 citing limited visibility, while Wells Fargo cut its target to $19 as well citing the company's cost pressures. Barrington lowered its target but maintained an Outperform rating.
Analysts point to ongoing market challenges and headwinds impacting Dentsply Sirona's performance. The company is struggling with rising costs and competitive pressures in the dental equipment market. Looking ahead, slowing revenue growth forecasts suggest these issues could persist.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。